Liberty Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.80 M
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.99 Cr
- Satisfied Charges ₹ 13.62 Cr
- Revenue Growth %
- Profit Growth -165.96%
- Ebitda -165.96%
- Net Worth -7.22%
- Total Assets 1.14%
About Liberty Pharma
Liberty Pharma Private Ltd. (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 May 1995 and has a history of 29 years and nine months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.80 M.
The company currently has active open charges totaling ₹10.99 Cr. The company has closed loans amounting to ₹13.62 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kulveer Hurkat, Rajendra Jalan, and Seema Jain serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24231WB1995PTC071347
- Company No.
071347
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 1995
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Liberty Pharma?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Rajendra Jalan | Director | 20-Sep-2021 | Current |
Kulveer Hurkat | Director | 31-Mar-2023 | Current |
Seema Jain | Director | 25-Nov-2021 | Current |
Financial Performance of Liberty Pharma.
Liberty Pharma Private Ltd., for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 165.96% decrease in profit. The company's net worth dipped by a decrease of 7.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Liberty Pharma?
In 2023, Liberty Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹109.90 M
₹136.22 M
Charges Breakdown by Lending Institutions
- Others : 10.99 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
16 Dec 2021 | Others | ₹10.99 Cr | Open |
11 Oct 2017 | Others | ₹11.02 Cr | Satisfied |
10 Dec 2005 | Icici Bank Ltd. | ₹2.60 Cr | Satisfied |
How Many Employees Work at Liberty Pharma?
Unlock and access historical data on people associated with Liberty Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Liberty Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Liberty Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.